David Negrete, MD | |
Msc08 4640 1 University Of New Mexico, Albuquerque, NM 87131-1804 | |
(505) 272-4814 | |
(505) 272-0240 |
Full Name | David Negrete |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | Msc08 4640 1 University Of New Mexico, Albuquerque, New Mexico |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356064877 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
David Negrete, MD Msc08 4640 1 University Of New Mexico, Albuquerque, NM 87131-0001 Ph: (505) 272-4814 | David Negrete, MD Msc08 4640 1 University Of New Mexico, Albuquerque, NM 87131-1804 Ph: (505) 272-4814 |
News Archive
By charting the differing fates of individual T cells, researchers have shown that previously unpredictable aspects of the adaptive immune response can be effectively modeled.
Impax Laboratories, Inc. today announced that it has reached agreement with Endo Pharmaceuticals and Penwest Pharmaceuticals to settle pending U.S. litigation with regard to the production and sale of generic formulations of OPANA ER (oxymorphone hydrochloride) Extended Release tablets.
The ALS Therapy Development Institute announced today that it is supporting a new awareness campaign driven by several ALS patients diagnosed with the progressive neurodegenerative disease commonly known as Lou Gehrig's disease before the age of 30. This campaign, called "Young Faces of ALS," is designed and led by a group of seven young men and women and will consist of a group effort to visit each of the 30 Major League Baseball parks during the 2010 baseball season.
An international research team led by scientists at the University of Alabama at Birmingham has identified a potential target for therapeutics that might help slow the progression of Parkinson's disease.
› Verified 7 days ago